In this issue, Ong and colleagues report on the effects of a 2006 Medicare ban on benzodiazepines for enrollees with Medicare Part D coverage. The ban was originally expected to save costs and reduce adverse drug effects. The authors found decreased benzodiazepine use but no reduction in adverse effects of the drug, and they report that overall costs for psychotropic medications increased. Other published reports on the benzodiazepine ban similarly suggest that clinical outcomes are not improved. The benzodiazepine ban is expected to be eliminated in 2013 under the Patient Protection and Affordable Care Act.